Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma

Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients

(2020) Mariaelena Capone et al.   Journal of Translational Medicine

High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a)

(2019) Viola Franke et al.   INTERNATIONAL JOURNAL OF CANCER

Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience

(2019) Raphael J. Louie et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition

(2019) Victoria A. Jennings et al.   MOLECULAR THERAPY

Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma

(2019) Praveen K. Bommareddy et al.   OncoImmunology

Correlates of response and outcomes with talimogene laherperpvec

(2019) Alice Y. Zhou et al.   JOURNAL OF SURGICAL ONCOLOGY

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

(2019) Robert H. I. Andtbacka et al.   Journal for ImmunoTherapy of Cancer

Efficacy of Talimogene Laherparepvec (T-VEC) Therapy in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion Size

(2019) Sabran J. Masoud et al.   ANNALS OF SURGICAL ONCOLOGY

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

(2019) David Liu et al.   NATURE MEDICINE

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

(2018) Jason Chesney et al.   JOURNAL OF CLINICAL ONCOLOGY

Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond

(2018) Kristina Buder-Bakhaya et al.   Frontiers in Immunology

Melanoma Immunotherapy: Next-Generation Biomarkers

(2018) Sabrina A. Hogan et al.   Frontiers in Oncology

60PResponse rates with talimogene laherparepvec (T-VEC) monotherapy in patients (pts) with stage IIIB–IVM1c melanoma previously treated with checkpoint inhibitor (CPI) therapy: Retrospective analysis of two clinical trials

(2018) H Gogas et al.   ANNALS OF ONCOLOGY

Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience

(2018) Matthew C. Perez et al.   ANNALS OF SURGICAL ONCOLOGY

Current status and perspectives in immunotherapy for metastatic melanoma

(2017) Riccardo Marconcini et al.   Oncotarget

Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial

(2016) Robert H. I. Andtbacka et al.   ANNALS OF SURGICAL ONCOLOGY

Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma

(2016) Adil I. Daud et al.   JOURNAL OF CLINICAL INVESTIGATION

The immune system and cancer evasion strategies: therapeutic concepts

(2016) S. Muenst et al.   JOURNAL OF INTERNAL MEDICINE

Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015

(2016) J. Galon et al.   Journal of Translational Medicine

Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial

(2016) Kevin Harrington et al.   OncoTargets and Therapy

Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy

(2016) Hasan Rehman et al.   Journal for ImmunoTherapy of Cancer

Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study

(2016) Howard L. Kaufman et al.   Journal for ImmunoTherapy of Cancer

A Threshold Level of Intratumor CD8 + T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1

(2015) Shin Foong Ngiow et al.   CANCER RESEARCH

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

A new paradigm for tumor immune escape: β-catenin-driven immune exclusion

(2015) Stefani Spranger et al.   Journal for ImmunoTherapy of Cancer

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Immunotype and Immunohistologic Characteristics of Tumor-Infiltrating Immune Cells Are Associated with Clinical Outcome in Metastatic Melanoma

(2012) G. Erdag et al.   CANCER RESEARCH

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma

(2009) Howard L. Kaufman et al.   ANNALS OF SURGICAL ONCOLOGY